CommercialCoverageMedium impact
08.00.51l, Enzyme Replacement for the Treatment of Gaucher's Disease
Independence Blue Cross·Hematology, Oncology, Genetics·Medical Policy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.51l regarding Enzyme Replacement for the Treatment of Gaucher's Disease has been reissued effective 05/28/2025. Without access to the full policy text content, the specific coverage changes, billing code requirements, or prior authorization updates cannot be determined. The billing team must review the complete policy document to identify coverage criteria, approved enzymes, authorization requirements, and any changes from the previous version.
Action Required
By 05/28/2025: Billing team must obtain and review the complete policy text for 08.00.51l at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=05&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-51l. Identify specific HCPCS J-codes for enzyme replacement therapies covered, prior authorization requirements, medical necessity documentation requirements, and any changes from the previous policy version. Update billing software, encounter forms, and provider alerts accordingly. Flag any claims for Gaucher's disease enzyme replacement to compliance team for review during transition period.